GlassScriptPhysician profile
Mark A Henry
NPI 1972587251
$1,808.85
in general payments reported to CMS, 2019-2025
22 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $195 · 2021: $404 · 2022: $119 · 2023: $218 · 2024: $241 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845 · Entertainment: $17.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.23 |
| Entertainment | $17.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $329.08 | 2019-2025 | Clareon, Hydrus Microstent, Tryptyr |
| Abbvie INC. | $233.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $153.07 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $148.33 | 2019-2021 | |
| Allergan, INC. | $141.74 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $127.36 | 2019-2021 | |
| Biotissue Holdings INC. | $94.29 | 2021-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.03 | 2019-2021 | |
| Oyster Point Pharma, INC. | $64.06 | 2022-2024 | Tyrvaya |
| Amgen INC. | $64.04 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $63.89 | 2019-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $53.14 | 2019-2025 | Tecnis Iol |
| Harrow Eye, LLC | $47.48 | 2025 | Vevye, Triesence |
| Carl Zeiss Meditec USA, INC. | $36.02 | 2021 | |
| Dompe US, INC. | $34.87 | 2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $28.40 | 2021-2023 | |
| Tarsus Pharmaceuticals, INC. | $23.56 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $22.12 | 2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $20.87 | 2022 | |
| Sight Sciences, INC. | $20.24 | 2025 | Omni Surgical System |
| Optos, INC. | $17.17 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Phathom Pharmaceuticals, INC. | $16.88 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.